ATE387445T1 - Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren - Google Patents

Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren

Info

Publication number
ATE387445T1
ATE387445T1 AT03785789T AT03785789T ATE387445T1 AT E387445 T1 ATE387445 T1 AT E387445T1 AT 03785789 T AT03785789 T AT 03785789T AT 03785789 T AT03785789 T AT 03785789T AT E387445 T1 ATE387445 T1 AT E387445T1
Authority
AT
Austria
Prior art keywords
pyridino
pyrimidine derivatives
fgfr inhibitors
kdr
selective
Prior art date
Application number
AT03785789T
Other languages
English (en)
Inventor
Jin-Jun Liu
Kin-Chun Luk
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE387445T1 publication Critical patent/ATE387445T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03785789T 2002-12-20 2003-12-11 Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren ATE387445T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43496902P 2002-12-20 2002-12-20
US51361503P 2003-10-23 2003-10-23

Publications (1)

Publication Number Publication Date
ATE387445T1 true ATE387445T1 (de) 2008-03-15

Family

ID=32685355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03785789T ATE387445T1 (de) 2002-12-20 2003-12-11 Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren

Country Status (15)

Country Link
US (1) US7098332B2 (de)
EP (1) EP1581531B1 (de)
JP (1) JP2006511563A (de)
KR (1) KR100763298B1 (de)
AR (1) AR042532A1 (de)
AT (1) ATE387445T1 (de)
AU (1) AU2003294830B2 (de)
BR (1) BR0317480A (de)
CA (1) CA2508951A1 (de)
DE (1) DE60319430T2 (de)
ES (1) ES2300639T3 (de)
MX (1) MXPA05006437A (de)
PL (1) PL377661A1 (de)
RU (1) RU2345077C2 (de)
WO (1) WO2004056822A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
EP1749004B1 (de) * 2004-05-04 2007-09-19 Warner-Lambert Company LLC Pyrrolylsubstituierte pyrido[2,3-d]pyrimidin-7-one und derivate davon als therapeutische mittel
WO2006068770A1 (en) * 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
US20090312321A1 (en) * 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
GEP20115306B (de) * 2006-09-15 2011-10-10 Pfizer Prod Inc
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
HRP20170430T1 (hr) 2012-06-13 2017-06-16 Incyte Holdings Corporation Supstituirani triciklični spojevi kao inhibitori fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
WO2014144737A1 (en) * 2013-03-15 2014-09-18 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PL2986610T4 (pl) 2013-04-19 2019-06-28 Incyte Holdings Corporation Bicykliczne heterocykle jako inhibitory FGFR
JP6203954B2 (ja) * 2013-10-25 2017-09-27 ノバルティス アーゲー Fgfr4阻害剤としての縮環二環式ピリジル誘導体
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
WO2015144804A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations
AU2015304465B2 (en) 2014-08-18 2019-05-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Fgfr4阻害剤としての縮環二環式ピリジル誘導体の使用
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI834020B (zh) 2015-02-10 2024-03-01 英商阿斯迪克治療公司 新穎組成物
MY197720A (en) 2015-02-20 2023-07-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
ES2887148T3 (es) 2015-03-25 2021-12-21 Nat Cancer Ct Agente terapéutico contra el cáncer de vías biliares
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2017050864A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv New compounds
CN108367000A (zh) * 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
KR102583737B1 (ko) * 2017-03-03 2023-09-26 오클랜드 유니서비시즈 리미티드 Fgfr 키나제 저해제 및 약학적 용도
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019015593A1 (zh) * 2017-07-19 2019-01-24 江苏奥赛康药业股份有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
MX2020008610A (es) 2018-03-28 2020-09-21 Eisai R&D Man Co Ltd Agente terapeutico para carcinoma hepatocelular.
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Fgfr阻害剤の塩
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
MX2021006841A (es) 2018-12-10 2021-07-02 Ideaya Biosciences Inc Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?.
EP3902803B1 (de) 2018-12-27 2023-02-01 Les Laboratoires Servier Aza-heterobicyclische inhibitoren von mat2a und verfahren zur behandlung von krebs
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JOP20210317A1 (ar) * 2019-05-31 2023-01-30 Servier Lab مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115298177B (zh) 2019-10-11 2025-01-17 因赛特公司 作为cdk2抑制剂的双环胺
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Fgfr阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4054579A1 (de) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur behandlung von krebsarten, die resistenz gegen kinase-inhibitoren erworben haben
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112062770A (zh) * 2020-08-21 2020-12-11 台州学院 一种稠环二氢吡啶酮的制备方法
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
EP4352060A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69515898T2 (de) * 1994-11-14 2000-08-17 Warner-Lambert Co., Morris Plains 6-ARYL-PYRIDO[2,3-d]PYRIMIDINE UND -NAPHTHYRIDINE ZUR HEMMUNG DER DURCH PROTEIN-TYROSIN-KINASE HERVORGERUFENEN ZELLVERMEHRUNG
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
NZ510760A (en) 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
AU753717B2 (en) 1999-03-16 2002-10-24 Shell Internationale Research Maatschappij B.V. Process for the purification of propylene oxide
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
AU2001278908A1 (en) 2000-08-04 2002-02-18 Warner Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin 7-ones
WO2002012238A2 (en) 2000-08-04 2002-02-14 Warner-Lambert Company 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES
JP4141830B2 (ja) 2000-08-31 2008-08-27 エフ.ホフマン−ラ ロシュ アーゲー 細胞増殖の阻害剤としての7−オキソ−ピリドピリミジン類
US20030165873A1 (en) * 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system

Also Published As

Publication number Publication date
KR20050088202A (ko) 2005-09-02
US20040122029A1 (en) 2004-06-24
CA2508951A1 (en) 2004-07-08
EP1581531B1 (de) 2008-02-27
ES2300639T3 (es) 2008-06-16
DE60319430D1 (de) 2008-04-10
BR0317480A (pt) 2005-11-16
US7098332B2 (en) 2006-08-29
PL377661A1 (pl) 2006-02-06
AU2003294830A1 (en) 2004-07-14
MXPA05006437A (es) 2005-08-19
AR042532A1 (es) 2005-06-22
RU2345077C2 (ru) 2009-01-27
EP1581531A1 (de) 2005-10-05
KR100763298B1 (ko) 2007-10-04
JP2006511563A (ja) 2006-04-06
WO2004056822A1 (en) 2004-07-08
RU2005122901A (ru) 2006-02-27
AU2003294830B2 (en) 2009-06-11
DE60319430T2 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
ATE387445T1 (de) Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren
DE60317466D1 (de) Nicotinamid-derivate als pde4-hemmer
DE60315886D1 (de) Substituierte pyrazin- oder pyridin-derivate als glukokinase-aktivatoren
DE60332396D1 (de) PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN
CY2017015I2 (el) ΕΤΕΡΟΑΡΥΛΟ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΔΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΜΙΔΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ JANUS
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE472536T1 (de) Pyridin- und pyrimidin-derivate
ATE387446T1 (de) Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE481402T1 (de) Pyrazolopyridin-derivate
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE452892T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
ATE433977T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate
ATE309247T1 (de) Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate
ATE462694T1 (de) Cox-2-inhibierende pyridinderivate
ATE362930T1 (de) Nicotinamid-derivate verwendbar als pde4 inhibitoren
GB0317516D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
NO20035206L (no) Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
NO20055518D0 (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
GB0317509D0 (en) Nicotinamide derivatives useful as PDE4 inhibitors
IS7366A (is) Nikótínamíð afleiður nytsamlegar sem PDE4 hindrar
GT200300035A (es) Derivados de nicotinamida utiles como inhibidores de pde4

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1581531

Country of ref document: EP

REN Ceased due to non-payment of the annual fee